Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rimegepant for acute treatment of migraine in children and adolescents
CTR20222224Phase 3Active
- Sponsor
- Biohaven Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rimegepant in migraine, sponsored by Biohaven Ltd.. Started Mar 2023; status: active.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20222224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222224.